Kornimate/medical-research-clean huggingface dataset:
single-cell transcriptomics of the peritoneal microenvironment of colorectal pc

Conditions: Peritoneal Metastases

Summary: single cell transcriptomics of crc pc samples

research methodology before inclusion of patients, patients will be screened for the presence of hepatitis b, hepatitis c and hiv to ensure researcher safety. during cytoreductive surgery, a total of five samples of tumoral tissue will be acquired. three of those samples will be utilized for scrnaseq analysis, and two samples of a macrometastasis will be snap frozen and cryopreserved. single-cell rna-sequencing analysis we will comprehensively catalog the stromal cell types in the microenvironment of colorectal cancer peritoneal metastases utilizing single-cell rna sequencing (scrnaseq) on three samples (one of which should preferably originate from the omentum majus, to encompass milky spots) acquired from surgical waste material of patients undergoing cytoreductive surgery. after sample prelevation, samples will be transported as soon as possible while cooled and submerged in 10% pbs to the vib facilities, where single cell suspensions will be made according to standard protocols. after cell selection by facs (cd45+ and live/dead stain, to ensure a 50/50 mix of immune and stromal cells) and library prep, scrnaseq will be performed. single cell sequencing analysis will allow us to identify cell clusters that by usage of marker genes will be assigned to different known cell lineages. after annotation of data, a "landscape" of the composition of the tumor stroma will be acquired.

Eligibility criteria:
inclusion criteria: * patients undergoing crs+hipec for pc of colorectal origin exclusion criteria: * previous hipec/pipac
the predictive role of immune-inflammatory biomarkers and their interaction with the oxytocin system in trauma-related psychotherapy responsiveness

Conditions: Posttraumatic Stress Disorder

Summary: despite a range of treatments for posttraumatic stress disorder (ptsd), only a small proportion of patients reach full symptomatic remission. recent developments in the field of neuroscience have been providing compelling evidence to suggest that neurobiological determinants might influence not only the emergence of ptsd, but also its resistance to treatment. immune-inflammation regulatory processes were found to be active during recovery from ptsd, potentially through interactive relationship with the oxytocin secretion system. this innovative longitudinal study aims to examine the role of inflammatory biomarkers and their interactive effect with the oxytocin (ot) system on the development of ptsd and on treatment response among patients with ptsd symptoms undergoing psychotherapy treatment. patients (n = 100) suffering from trauma-related distress will be recruited from the trauma clinic in shalvata mental health center. participants will be followed for 12 weeks of once-a-week psychotherapy sessions. they will be measured for endogenous ot level and cytokines levels in saliva before and after sessions 1, 6, and 12, and will complete psychotherapy outcome self-report questionnaires following each of these sessions.


Eligibility criteria:
inclusion criteria: * minimum score of 33 on the ptsd symptoms questionnaire (pcl-5). * anticipated 12-24 psychotherapy sessions. exclusion criteria: * psychotic episode. * female patients: pregnancy or breastfeeding (according to self-report).
neoadjuvant hormonal therapy combined with chemoimmunotherapy

Conditions: HER2-positive Breast Cancer; ER-positive Breast Cancer

Summary: hormonal therapy administered before surgery in er-positive and her2-positive patients with breast cancer.

hormonal therapy with fulvestrant 500 mg to be administered before surgery with docetaxel, trastuzumab, and pertuzumab to determine pathological complete remission rate at the time of surgery in er-positive and her2-positive patients with breast cancer.

Eligibility criteria:
inclusion criteria: 1. patients ≥ 18 years of age with histologically, and radiographically confirmed non-metastatic er-positive (defined as ≥30% of positive cells) and her2-positive (defined as overexpression by immunohistochemistry (3+) or 2+ and positive by defined by fluorescence or dual in situ hybridization.) breast cancer with minimal tumor size over 2 cm (≥t2 lesion) to receive neoadjuvant chemotherapy recommended by the treating physician 2. eastern cooperative oncology group (ecog) performance status score \< 1 3. absolute neutrophil count \> 1500 mm3, platelet count ≥ 100×109 l, hemoglobin ≥ 8.5 g/dl 4. serum creatinine ≤1.5 times the upper limit of the normal range, total bilirubin ≤ 1.5 x uln (≤ 3 mg/dl if clinically diagnosed with gilbert syndrome) ast/alt ≤ 2.5 x uln (ast/alt ≤ 5x uln if clinically diagnosed with gilbert syndrome) 5. women of child-bearing potential (i.e., women who are pre-menoposaul or not surgically sterile) must have a negative serum pregnancy test within 2 weeks prior to beginning treatment exclusion criteria: 1. uncontrolled cardiac disease, such as angina, hypertension or significant arrhythmias 2. lvef (left ventricular ejection fraction) \< 50% on any prior assessment. note: assessment of lvef is done before and after trastuzumab-based chemotherapy as standard of care 3. pregnant or lactating females 4. inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements 5. concurrent severe illness such as active infection, or psychiatric illness/social situations that would limit safety and compliance with study requirements
application of machine learning models to reduce need for diagnostic eus or mrcp in patients with intermediate likelihood of choledocholithiasis

Conditions: Choledocholithiasis

Summary: machine learning predictive model can help in stratifying heterogenous intermediate likelihood group to reduce need for eus or mrcp in selected subgroup of patients.

the current guidelines for suspected choledocholithiasis are aimed to reduce the risk of patient receiving diagnostic ercp and reduce the risk of post ercp adverse events. in this process there is apparent increase in number of patients in the intermediate likelihood group requiring eus or mrcp. this can increase the health care utilization and cost of care for intermediate likelihood patients. the field of artificial intelligence in clinical medicine is evolving rapidly. the use of artificial intelligence based machine learning model is not adequately studied for prediction of choledocholithiasis. machine learning predictive model can help in stratifying heterogenous intermediate likelihood group to reduce need for eus or mrcp in selected subgroup of patients.

Eligibility criteria:
inclusion criteria: • individual 18 years or older with a suspected choledocholithiasis satisfying either asge or esge risk stratification criteria of intermediate likelihood undergoing eus or mrcp exclusion criteria: * patients having co-exiting disease of pancreato biliary system other than gall stones and choledocholithiasis which include chronic pancreatitis, biliary stricture, pancreatobiliary malignancy, portal biliopathy * patients having underlying chronic liver diseases * pregnancy and breast feeding * previous history of cholecystectomy
cb1 receptors in human brown adipose tissue

Conditions: Obesity

Summary: this study investigates cannabinoid cb1 receptors in human brown adipose tissue (bat) and other tissues using positron emission tomography (pet) imaging. subjects will be scanned in room temperature conditions and during controlled cold exposure, and the density of cb1 receptors in bat and other tissues will be quantified. the investigators hypothesize, that cannabinoid signaling is increased in cold conditions, when bat is metabolically active. understanding the mechanisms of bat activation and the role of endocannabinoids in humans is important and beneficial in fighting against the epidemic of obesity and diabetes.

endocannabinoids have an important role in regulating energy balance and metabolism. cannabinoid 1 receptors (cb1) are found in several tissues such as brown adipose tissue (bat). endocannabinoids and cb1 receptors participate in the control of lipid and glucose metabolism, and blockage of cb1 receptors has been found to improve metabolic factors linked to obesity and cardiovascular disease, making cb1 antagonists potential drugs against obesity and diabetes. in this study the investigators use a pet radiotracer \[18f\]fmpep-d2, which binds to cb1 receptors in vivo, to quantify the cb1 receptor density in bat, white adipose tissue, muscle and the brain. this study is done once in warm conditions and once during controlled cold exposure. to verify whether the subject has metabolically active bat, an additional pet scan with the radiotracer \[18f\]fdg is performed.

Eligibility criteria:
inclusion criteria: * healthy volunteer * group 1: bmi 20-26 kg/m2, group2: bmi 27-40 kg/m2 exclusion criteria: * bmi \ 40 kg/m2 * any chronic disease that could affect the study outcome, including medicated type 2 diabetes * mental disorder or poor compliance * eating disorder or excessive use of alcohol, tobacco smoking or drug use * past dose of radiation * presence of any ferromagnetic objects that would make mr imaging contraindicated * any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results

Keywords: brown adipose tissue cannabinoid receptor pet imaging metabolism
pain sensitivity in nrem parasomnia (nocisomnie)

Conditions: NREM Parasomnia; Sleepwalking; Sleep Terror

Summary: non rapid eye movement (nrem) sleep parasomnias (sleepwalking and sleep terrors) are frequent and disabling sleep disorders characterized by arousal specifically from slow wave sleep (sws) with dissociated brain activity that may be related to lower nociceptive state. the investigators recently reported frequent subjective complaints of chronic pain, migraine and headache during wakefulness in adult sleepwalkers. they also described frequent analgesia during severe and injuring episodes, suggesting a relationship between dissociated brain activity and nociceptive dysregulation. however, this study did not included objective nociceptive measures and the retrospective assessment of perceived pain during parasomnia episodes over a lifetime span might also introduce a recall bias. the aims of the present study are to measure objective pain sensitivity in patients with nrem parasomnias and matched controls during 1) parasomniac episodes, 2) light nrem sleep and sws, and 3) wakefulness. fifteen adults with severe nrem parasomnia and 15 age and sex-matched controls will be recruited. a 25 hours (8 am to 9 am) sleep deprivation protocol followed by auditory stimulations during sws will be used to trigger parasomniac episodes. thermoalgic stimulations of graduate intensity will be applied during wakefulness (8 pm) to determine the nociceptive threshold. during the recovery sleep following the sleep deprivation, the investigators will apply repeated subthreshold thermoalgic stimulations in nrem stage 2, sws and triggered parasomniac episodes and report the behavioural/neurophysiologic nociceptive responses. the investigators hypothesized a lower nociceptive threshold during wakefulness in sleepwalkers and a decrease of the arousabiliy during sws and parasomniac episodes. this study may help to better understand the etiology and mechanisms underlying the clinical enigma of the nociceptive dysregulation in nrem sleep parasomnias.


Eligibility criteria:
inclusion criteria: * subject from 18 years-old to 45 years-old * affiliated to social security * written informed consent \* case specific inclusion criteria : * nrem parasomnia diagnosed according to the international classification of sleep disorders 3rd edition (icsd-3) criteria and confirmed by polysomnography assessment * frequent symptomatology (at least 1 episode by week in the past 3 months) \* control specific inclusion criteria : * no medical history of nrem parasomnia exclusion criteria: * known skin allergy to metal * use of psychotropic drugs during the 15 days before the inclusion * use of analgesic drugs during the 15 days before the inclusion * a diagnosis of sleep apnea syndrome, periodic limb movements or restless legs syndrome present more than twice a week * medical history of epilepsy * non stable psychiatric disorder * pregnancy, breastfeeding * subject deprived of liberty or protected by law (tutorship, curatorship).
a study of pm8002 (anti-pd-l1/vegf) in combination with chemotherapy in patients with nsclc

Conditions: NSCLC

Summary: pm8002 is a bispecific antibody targeting pd-l1 and vegf. this is a phase ii study to evaluate the efficacy and safety of pm8002 in combination with pemetrexed and carboplatin in patients with egfr-mutant locally advanced or metastatic non-squamous nsclc who have failed to egfr-tki treatment.

this study is a phase ii, single-arm study, 64 participants were enrolled as of 6 feb 2024, and recruitment was completed.

Eligibility criteria:
inclusion criteria: 1. signed informed consent form before any trial-related processes. 2. age ≥ 18 years male or female. 3. have a histologically or cytologically confirmed stage iiib/iiic nsclc that is unresectable and not fit for radical concurrent chemoradiotherapy, or metastatic non-squamous nsclc (iv). 4. with egfr mutation confirmed by tumor histology or cytology or hematology prior to egfr-tki treatment. 5. egfr-tki resistance, confirmed by recist v1.1. 6. have adequate organ function. 7. the investigator confirms at least one measurable lesion according to recist v1.1. a measurable lesion located in the field of previous radiation therapy or after local treatment may be selected as a target lesion if progression is confirmed. 8. the eastern cancer cooperative group (ecog) performance score of 0 or 1. exclusion criteria: 1. squamous cell \> 10%. if small cell types are present, the subject is not eligible for inclusion. 2. have other driving gene mutations that can obtain effective treatment. 3. have previously received systemic anti-tumor treatment other than egfr-tki for advanced non-squamous nsclc. 4. have received systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to the first dose of study drugs. 5. have received egfr-tki treatment, within 14 days prior to the first dose of study drugs 6. anticoagulant or thrombolytic agent within 10 days prior to the first dose of study drugs. 7. evidence and history of severe bleeding tendency or coagulation dysfunction. 8. the toxicity of previous anti-tumor therapy has not been alleviated. 9. symptomatic central nervous system metastases (cns) metastasis and/or cancerous meningitis. 10. have suffered from the second primary active malignant tumor in the past 5 years.
erythromycin versus gastric lavage to improve quality of endoscopy in patients with upper gastrointestinal bleeding

Conditions: Gastrointestinal Hemorrhage; Hematemesis

Summary: the researchers will investigate whether erythromycin infusion is better than gastric lavage prior to emergency endoscopy to improve the quality of examination in patients with upper gastrointestinal bleeding.

the researchers will investigate whether erythromycin infusion is better than gastric lavage prior to emergency endoscopy to improve the quality of examination in patients with upper gastrointestinal bleeding. one hundred and twenty-two patients admitted within 12 hours after hematemesis will be randomly assigned to receive erythromycin infusion or gastric lavage by nasogastric tube prior to emergency endoscopy. the endoscopic procedures will be recorded on digital video disc (dvd). two endoscopists blinded to the cleansing strategy will assess the quality of examination of the upper gastrointestinal tract by using scales designed by frossard and avgerinos . secondary endpoints will be the need for a second-look endoscopy, the mean number of blood units transfused, the need of surgery or arteriography, and the mean duration of hospitalization

Eligibility criteria:
inclusion criteria: * recent hematemesis (\<12 hours) exclusion criteria: * macrolides allergy * pregnancy or lactation * treatment with terfenadine, astemizole or cyclosporine * prior gastrectomy

Keywords: upper gastrointestinal bleeding endoscopy erythromycin gastric lavage
treatment of temporomandibular dysfunction with hypertonic dextrose injection

Conditions: Temporomandibular Joint Disorders

Summary: dysfunction of the jaw, associated with pain in the jaw or about the jaw in the face can be quite long lasting and debilitating. dextrose injection with a small needle has been notably helpful in preliminary studies in reducing pain and improving jaw function. this randomized trial will compare dextrose injection with sterile water injection for temporomandibular(jaw) dysfunction, also known as tmd.

longitudinal studies of subjects with temporomandibular dysfunction show a general pattern of symptom diminishment, especially in the elderly. however studies out to 2-8 years show residual symptoms in many and nearly 25% with unabated symptoms. dextrose injection has been utilized empirically for many years and a marked reduction in pain and luxation after intra-articular and pericapsular dextrose injection has been reported in a recent rct. however, small study size and lack of a non injection control have prevented any definitive conclusions as the additional efficacy of including dextrose in the injectate. the mechanism of action of dextrose injection was originally thought to be via a brief stimulation of the inflammatory cascade with resultant production of growth factors. however, non-inflammatory dextrose effects on growth factor production have been demonstrated, and, more recently, dextrose has been found to treat neurogenic inflammation (pain from upregulation of the trpv1 receptor on peptidergic nerves). this has the theoretical benefit of reducing pain, regardless of the status and position of the intraarticular cartilage or degree of degenerative change of the tmd. the primary goal of this study is to evaluate the ability of dextrose injection versus saline injection to reduce pain and improve functional complaints referable to the temporomandibular joint.

Eligibility criteria:
inclusion criteria: more than 3 month history of : * facial pain nrs rating \> 5/10 * jaw symptom rating \> 5/10 * jaw function issues seen on examination exclusion criteria: * any potential acute dental issue * rheumatic inflammatory disease * chronic intake of nsaids or corticosteroids. * pain in other body location worse than jaw pain * pain 10/10 in other body location.

Keywords: tmd temporomandibular dextrose prolotherapy
safe use of heparin sodium in patients with chronic renal failure.

Conditions: Chronic Renal Failure

Summary: the heparin form a complex with a plasma protein, antithrombin iii (atiii), which is an endogenous anticoagulant. this complex inhibits the formation of thrombin and accelerates its destruction. moreover, heparin and other proteases atiii inactivate the clotting cascade, especially the anti-activated factor x. the end result of these actions is the inhibition of biochemical training and synthesis of certain clotting factors that activators of critical functions in the genesis of a blood clot. patients with chronic renal failure (crf) who use the treatment of hemodialysis need a system of anticoagulation with the direct thrombin inhibitor and / or heparinóides to prevent thrombosis. based on clinical studies, to control the level of plasma heparin in patients with crf is essential. evidence of clotting as aptt, tp, act and proof of the activity of anti-factor xa should be used as a substrate of protection for those patients on hemodialysis.


Eligibility criteria:
inclusion criteria: * adults of both sexes, regardless of color or social class; * age above 18 years; * patients who agree to participate in the study and signed the free and informed consent (attached); * insufficient patients in chronic renal dialysis scheme (3 times per week); * low chronic renal indication of anticoagulant during dialysis. exclusion criteria: * not agree to the terms described in informed consent; * patients with sensitivity to heparin sodium; * volunteer search with hypersensitivity to benzyl alcohol; * patients with a history of bleeding or change in blood clotting that can aggravate or terminate the clinical picture, such as tables of gastric ulcer; * patients with a history of peptic ulcer; * patients with cancer of any etiology, because of the possibility of compromising the function of the variable coagulation; * patients in a period of pregnancy and postpartum; * individuals with genetic abnormality of clotting system; * patients polytraumatized; * patients in use of glucocorticoids for at least 1 month; * patients in use of other anticoagulants; * patients with high rate of bleeding; * patients undergo any surgery performed less than 15 days because of the risk of the formation of hematomas at the site of surgery; * patients in use of drugs that affect the hemostasis; * in addition to these, clinical characteristics that the medical criteria, can interfere with the study.

Keywords: safety non-inferiority
vibrotactile stimulation with saphenus device

Conditions: Amputation

Summary: to determine the benefit of the vvibrotactile sensory feedback device.

in the united states, approximately 150.000 patients undergo a lower extremity amputation annually. with a high change of developing neuropathic pain, decreased mobility due to the missing limb and therefore depressed mental wellbeing, lower extremity amputations are debilitating the patient on multiple facets. from the usage of non-mechanical prosthetic wear, meaningful improvements have been made in surgical amputee care in the recent decades. osseointegration, and later regenerative nerve surgical techniques like targeted muscle reinnervation (tmr) and regenerative peripheral nerve interface (rpni) have led to major improvements in the mobility of lower limb amputees, by introducing myoeletric prosthetics. although technological advances have let to improved motoric function and motor control over artificial limbs, sensory feedback is still a very complex aspect of regaining full control over the missing limb. recently, introduced as a technical variation on tmr, targeted sensory reinnervation is based on reinnervation of a defined skin area by another sensory nerve. recently, application of vibrotactile feedback, connected to the lower extremity prosthetic socket, has shown promising results in regaining proprioception in the missing limb, resulting in improved walking ability and pain. however, targeted sensory reinnervation (tsr) is a novel surgical technique which is not always possible to perform and not available to every lower extremity amputee. therefore, this study aims to investigate whether this vibrotactile sensory feedback device improves gait and pain in major lower limb amputee population regardless of whether tsr has been conducted.

Eligibility criteria:
inclusion criteria: * english-speaking * major lower limb amputee * willing and able to participate exclusion criteria: * age under 18